2023 World Conference on Lung Cancer (Posters)-P2.09. Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis

P2.09. Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis - PDF(Slides)

Back to course

Pdf Summary

In a subset analysis of the LASER301 phase 3 study, lazertinib, a third-generation tyrosine kinase inhibitor (TKI), demonstrated better efficacy and tolerability compared to the first-generation TKI gefitinib in Asian patients with epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). The study included a total of 258 Asian patients, with 129 receiving lazertinib and 129 receiving gefitinib.<br /><br />The primary endpoint of the study was investigator-assessed progression-free survival (PFS), which was significantly longer in the lazertinib group compared to the gefitinib group. The median PFS was 20.6 months in the lazertinib group and 9.7 months in the gefitinib group. Similar results were observed in a sensitivity analysis using blinded independent central review.<br /><br />Secondary endpoints, such as overall survival (OS), objective response rate (ORR), and disease control rate (DCR), also favored lazertinib. Median OS was not reached in either group at the time of data cutoff.<br /><br />Intracranial responses were evaluated in patients with measurable brain disease at baseline. Lazertinib showed a higher intracranial objective response rate (ORR) and disease control rate (DCR) compared to gefitinib. Median intracranial duration of response (DoR) was not reached in the lazertinib group.<br /><br />The safety profile of lazertinib was similar to that observed in the overall LASER301 population. The most common adverse events (AEs) associated with lazertinib were paresthesia, rash, and pruritus.<br /><br />Overall, this analysis of Asian patients in the LASER301 study demonstrated that lazertinib was more effective than gefitinib as a first-line treatment for EGFR-mutated advanced NSCLC. Lazertinib also showed favorable intracranial responses in patients with brain metastases. The safety profile of lazertinib was well-tolerated.

Asset Subtitle

Thanyanan Reungwetwattana

Meta Tag

Speaker Thanyanan Reungwetwattana

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

LASER301 phase 3 study

lazertinib

TKI

gefitinib

Asian patients

EGFR-mutated NSCLC

progression-free survival

intracranial responses

safety profile

adverse events